Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression
- First Online:
- 238 Downloads
High placebo response rates are a confound in treatment trials for major depressive disorder (MDD). A method for prospective identification of placebo responders could enhance the efficiency of clinical trials.
The objective was to identify the neurophysiological, symptomatic, and cognitive characteristics of subjects who were likely to respond to placebo in clinical trials for MDD.
Fifty-one subjects with MDD were treated in clinical trials with either fluoxetine (n=24) or venlafaxine (n=27) versus placebo. All subjects underwent pretreatment assessment with quantitative electroencephalographic (QEEG) power and cordance, as well as symptom ratings and neuropsychological testing. After a 1-week single-blind placebo lead-in, subjects were randomized to double-blind placebo controlled treatment with a medication or placebo. At the end of 8 weeks, the blind was broken and treatment response assessed. Response was defined by a final Hamilton Depression Rating Scale score of ≤10.
Of the medication-treated and placebo-treated subjects, 52% (13/25) and 38% (10/26) responded. Placebo responders had lower pretreatment frontocentral cordance in the theta frequency band than all other subjects (P<0.006) and medication responders in particular (P<0.004). Placebo responders also had faster cognitive processing time, as assessed by neuropsychological testing, and lower reporting of late insomnia (P<0.03). Exploratory examination of a multiple variable model for predicting placebo response was conducted using logistic regression, in which these three pretreatment measures accurately identified 97.6% of eventual placebo responders.
These findings suggest that combined clinical, neurophysiological, and cognitive assessments of prospective subjects for clinical trials may be useful for identifying MDD subjects who are likely to show robust response to placebo. Prospective validation of these results in a larger, independent sample of subjects is necessary to establish the reliability and usefulness of this method for prospective identification of placebo responders.
KeywordsDepression Medication treatment Placebo response Quantitative EEG Cordance Cognitive processing Insomnia
- Beecher HK (1955) The powerful placebo. JAMA 159:1602–1606Google Scholar
- Cook IA, O’Hara R, Uijtdehaage S, Mandelkern M, Leuchter AF (1998) Assessing the accuracy of topographic EEG mapping for determining local brain function. EEG Clin Neurophys 107:404–414Google Scholar
- Kaplan E, Goodglass H, Weintraub S (1983) Boston Naming Test. Lea & Febiger, Philadelphia, PAGoogle Scholar
- Lezak MD (1983) Neuropsychological Assessment. Oxford University, New YorkGoogle Scholar
- Michelson D, Holland P, Tepner R, Pemberton C (1999) Double-blind vs. single-blind placebo lead-in periods during panic disorder efficacy trials. Poster presented at the 39th Annual NCDEU Meeting. Boca Raton, FLGoogle Scholar
- Peselow ED, Sanfilipo MP, Difiglia C, Fieve RR (1992) Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 159:1848–1854Google Scholar
- Quitkin FM, Stewart JW, McGrath PJ (1993) Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 163:30–34Google Scholar
- Reitan RM (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276Google Scholar
- Rey A (1941) L’examen psychologique dans les cas d’encephalopathie traumatique. Arch Psychol 28:286–340Google Scholar
- Rey A (1964) L’examen clinique en psychologie. Pressess Universitiaires de France, ParisGoogle Scholar
- Shapiro AK, Shapiro E (1997) The Powerful Placebo: from Ancient Priest to Modern Physician. Johns Hopkins University, BaltimoreGoogle Scholar
- Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava MD, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P (1998) Use of pattern analysis to predict differential relapse of remitted patients with major depression during one year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 55:334–343CrossRefPubMedGoogle Scholar
- Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 12:643–662Google Scholar
- Wechsler D (1981) Manual for the Wechsler Adult Intelligence Scale—revised. Psychological Corporation, New YorkGoogle Scholar
- Wechsler D (1987) Manual for the Wechsler Memory Scale—revised. Psychological Corporation, New YorkGoogle Scholar
- Woodcock RW, Johnson MB (1977) Woodcock-Johnson Psycho-Educational Battery. DLM Teaching Resources, Allen, TexasGoogle Scholar
- Zimbroff DL, Mendez, G (2002) Patient and rater education about expectations in clinical trials (PREECT): an approach to reducing placebo response rates and improving signal detection in psychopharmacology trials. Poster presented at the 42nd Annual NCDEU Meeting. Boca Raton, FLGoogle Scholar